Lineage, Inc. Common Stock (LINE)vsStryker Corporation (SYK)
LINE
Lineage, Inc. Common Stock
$34.89
-1.30%
REAL ESTATE · Cap: $8.81B
SYK
Stryker Corporation
$327.65
+1.54%
HEALTHCARE · Cap: $125.72B
Smart Verdict
WallStSmart Research — data-driven comparison
Stryker Corporation generates 369% more annual revenue ($25.12B vs $5.36B). SYK leads profitability with a 12.9% profit margin vs -1.9%. SYK earns a higher WallStSmart Score of 65/100 (C+).
LINE
Hold36
out of 100
Grade: F
SYK
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LINE.
Margin of Safety
+16.8%
Fair Value
$393.59
Current Price
$327.65
$65.94 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Earnings expanding 55.9% YoY
Large-cap with strong market position
Strong operational efficiency at 27.2%
Generating 1.9B in free cash flow
Areas to Watch
0.0% earnings growth
ROE of -1.2% — below average capital efficiency
Revenue declined 0.2%
Distress zone — elevated risk
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : LINE
The strongest argument for LINE centers on Price/Book.
Bull Case : SYK
The strongest argument for SYK centers on EPS Growth, Market Cap, Operating Margin. Revenue growth of 11.4% demonstrates continued momentum.
Bear Case : LINE
The primary concerns for LINE are EPS Growth, Return on Equity, Revenue Growth.
Bear Case : SYK
The primary concerns for SYK are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
LINE profiles as a turnaround stock while SYK is a value play — different risk/reward profiles.
SYK is growing revenue faster at 11.4% — sustainability is the question.
SYK generates stronger free cash flow (1.9B), providing more financial flexibility.
Monitor REIT - INDUSTRIAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
SYK scores higher overall (65/100 vs 36/100) and 11.4% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Lineage, Inc. Common Stock
REAL ESTATE · REIT - INDUSTRIAL · USA
Lineage, Inc. (Ticker: LINE) is an innovative biotechnology company at the forefront of regenerative medicine, specializing in the development of advanced cell therapy solutions aimed at treating severe diseases such as eye disorders, spinal cord injuries, and cancer. Leveraging proprietary technologies and a strong commitment to strategic partnerships, the company is dedicated to revolutionizing patient care with its novel therapeutic approaches. As Lineage continues to enhance its diverse product pipeline and accelerate clinical research initiatives, it represents a compelling opportunity for institutional investors looking to support transformative advancements in healthcare.
Visit Website →Stryker Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.
Visit Website →Compare with Other REIT - INDUSTRIAL Stocks
Want to dig deeper into these stocks?